MacroGenics Inc (MGNX)
NASDAQ:MGNX
Want to see MGNX full AI Analyst Report?
MGNX Stock Chart & Stats
$3.46
-$0.07(-2.05%)
At close: 4:00 PM EST
$3.46
-$0.07(-2.05%)
Day’s Range― - ―
52-Week Range$1.19 - $5.08
Previous CloseN/A
Volume157.79K
Average Volume (3M)1.19M
Market Cap
$305.74M
Enterprise Value$221.70M
Total Cash (Recent Filing)$154.23M
Total Debt (Recent Filing)$36.51M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Aug 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,563,120
10 Day Avg. Volume625,094
30 Day Avg. Volume1,190,718
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit2.02
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$6.33Price Target Upside83.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$136.26M
Bulls Say, Bears Say
Bulls Say
Solid Revenue Base And Gross MarginA $157M TTM revenue run rate with ~63% gross margin produces durable gross profit to fund R&D and operations. High gross margins from collaboration and product-related streams support long-term pipeline investment and improve chances of reaching value-driving clinical milestones.
Non-dilutive Cash From Asset SaleThe $122.5M upfront sale of manufacturing assets materially strengthens liquidity without issuing equity, preserving ownership for existing shareholders. It reduces fixed-cost obligations, outsources capex, and provides runway to advance clinical programs while retaining manufacturing access via agreements.
Regulatory Clearance To Resume A Key TrialLifting the FDA partial hold on LINNET is a structural positive: it eliminates a regulatory constraint, lets the program generate additional safety/efficacy data, and maintains clinical momentum for lorigerlimab—critical for future partnering or approval paths and long-term pipeline value.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow signals ongoing funding needs absent material profitability improvement. Because cash burn tracks net losses rather than noncash items, the company will likely require repeated external financing or deal monetization, increasing dilution or financing costs over time.
Thin Equity Base With Elevated LeverageA thin equity base and ~1.72 debt/equity ratio reduce financial flexibility and raise refinancing risk. Even modest absolute debt becomes consequential against small equity, constraining capacity for large investments and increasing the likelihood of dilutive raises or restrictive covenant-driven decisions if losses persist.
Revenue Depends On Partner Milestones And Clinical SuccessSignificant revenue dependence on milestone and royalty payments makes cash flows lumpy and outcome-dependent. If partner trials, approvals, or commercial launches are delayed or fail, anticipated payments drop, limiting predictable funding for the independent advancement of the oncology pipeline and increasing execution risk.
MacroGenics News
MGNX FAQ
What was MacroGenics Inc’s price range in the past 12 months?
MacroGenics Inc lowest stock price was $1.19 and its highest was $5.08 in the past 12 months.
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is $305.74M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 45 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on May 13, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.574 by -$0.006.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is 0.03.
How many shares outstanding does MacroGenics Inc have?
MacroGenics Inc has 63,563,120 shares outstanding.
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.574. Following the earnings report the stock price went up 20.58%.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in MGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (83.04% Upside)
$6.33 (83.04% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
255.72%
12-Months-Change
Fundamentals
Return on Equity
-147.80%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Stock 12 Month Forecast
Average Price Target
$6.33
▲(83.04% Upside)
Technical Analysis
Ownership Overview
2.59% Insiders
12.16% Mutual Funds
21.53% Other Institutional Investors
58.86% Public Companies and
Individual Investors